STOCK TITAN

Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. reported that SVP and Chief Financial Officer Darren Snellgrove received new equity awards on July 1, 2026. He was granted options to purchase 127,432 shares of common stock at an exercise price of $77.01 per share, along with 41,554 restricted stock units (RSUs).

The options begin vesting one-fourth on the first vesting date and then in equal monthly installments over 48 months, while the RSUs vest in three equal annual installments starting on the first anniversary of the grant date. These are compensation-related grants, not open‑market purchases or sales, and increase the CFO’s potential future ownership if vesting and exercise conditions are met.

Positive

  • None.

Negative

  • None.
Insider Snellgrove Darren
Role SVP, Chief Financial Officer
Type Security Shares Price Value
Grant/Award Restricted Stock Units 41,554 $0.00 --
Grant/Award Option to Purchase Common Stock 127,432 $0.00 --
Holdings After Transaction: Restricted Stock Units — 41,554 shares (Direct, null); Option to Purchase Common Stock — 127,432 shares (Direct, null)
Footnotes (1)
  1. This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter. This option vests one-fourth on such date and then 1/48th monthly thereafter.
Stock options granted 127,432 shares Option to Purchase Common Stock granted to CFO on July 1, 2026
Option exercise price $77.01 per share Exercise price for 127,432 stock options granted to CFO
RSUs granted 41,554 units Restricted Stock Units granted to CFO on July 1, 2026
Options expiration July 1, 2036 Expiration date of CFO stock option grant
Option vesting structure 1/4 then 1/48 monthly Options vest one-fourth initially, then monthly over remaining term
RSU vesting structure 1/3 annually over 3 years RSUs vest in three equal annual installments from grant date anniversary
Option to Purchase Common Stock financial
"security_title: Option to Purchase Common Stock"
Restricted Stock Units financial
"security_title: Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
"conversion_or_exercise_price: 77.0100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant date financial
"This award vests one-third on the first anniversary of the grant date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vests financial
"This option vests one-fourth on such date and then 1/48th monthly thereafter."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Snellgrove Darren

(Last)(First)(Middle)
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/01/2026A41,55407/01/2027(1) (1)Common Stock41,554$041,554D
Option to Purchase Common Stock$77.0107/01/2026A127,43207/01/2027(2)07/01/2036Common Stock127,432$0127,432D
Explanation of Responses:
1. This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter.
2. This option vests one-fourth on such date and then 1/48th monthly thereafter.
Remarks:
/s/ James R. Oehler, Attorney-in-Fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did HALO (Halozyme) CFO Darren Snellgrove receive?

Darren Snellgrove received stock options for 127,432 shares and 41,554 restricted stock units. Both awards are tied to Halozyme common stock and represent compensation-based grants rather than open-market transactions, potentially increasing his future ownership if vesting and exercise conditions are satisfied.

What is the exercise price of the new Halozyme CFO stock options?

The new options granted to Halozyme CFO Darren Snellgrove have an exercise price of $77.01 per share. This means he can buy Halozyme common stock at $77.01 once the options vest, provided he remains eligible and exercises before the option expiration date in 2036.

How many RSUs were granted to the Halozyme CFO in this Form 4?

The Halozyme CFO was granted 41,554 restricted stock units. Each RSU represents a right to receive one share of Halozyme common stock, subject to vesting over time and continued service, rather than an immediate share issuance or cash transaction on the grant date.

How do the Halozyme CFO stock options vest under this grant?

The options granted to the Halozyme CFO vest one-fourth on the initial vesting date, then 1/48th monthly thereafter. This creates a four-year vesting schedule, encouraging longer-term employment and alignment with shareholder interests as more of the award becomes exercisable over time.

What is the vesting schedule for the Halozyme CFO restricted stock units?

The restricted stock units vest one-third on the first anniversary of the grant date and one-third on each of the next two anniversaries. This three-year, time-based schedule ties the CFO’s compensation to continued service and long-term company performance rather than short-term stock movements.

When do the new Halozyme CFO stock options expire?

The options granted to the Halozyme CFO expire on July 1, 2036. He can exercise vested options any time between vesting and this expiration date, subject to company policies and trading rules, after which any unexercised options will cease to be exercisable.